Expert Overviews
Panoramica dagli esperti internazionali di alcune delle più importanti sessioni presentate al congresso EASD.
Ask the Expert
In this overview:
83
Challenges in insulin therapy
307
Improving efficacy and adherence
1326
ADA/EASD consensus on management of hyperglycaemia in T2D
Ask the Expert
In this overview:
38
Dulaglutide in youth with type 2 diabetes: results of the AWARD-PEDS randomised, placebo-controlled trial
484
Ly3437943 (LY) a novel triple GIP/GLP-1/glucagon receptor agonist, provides glucose lowering and weight loss in patients with type 2 diabetes after 12 weeks of treatment
Ask the Expert
In this overview:
386
Post approval, observational, concurrent study to assess clinical effectiveness and safety of dapaglifozin in diabetic kidney disease: INTENSE - DAPA study
556
Effect of treatment with semaglutide, empaglifozin and the combination on kidney function in type 2 diabetes: impact of oxygenation and perfusion
744
Design of the Combination effect of Finerenone and Empaglifozin in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE)
866
Management of hyperglycemia in type 2 diabetes: ADA/EASD consensus Report 2022
1416
Development in eGFR trajectories in people with diabetic nephropathy
Ask the Expert